BRK.B vs. LLY: Berkshire Hathaway vs. Eli Lilly Stock Comparison
This page compares Berkshire Hathaway (BRK.B) with Eli Lilly (LLY) using performance and risk, profitability, financial strength, growth, dividends, and valuation metrics.
Performance
Cumulative Growth
Trailing Returns
Performance at a Glance
| Metric | BRK.B | LLY |
|---|---|---|
| 1-Year Return | -0.22% | 40.51% |
Risk
Drawdown
Risk at a Glance
| Metric | BRK.B | LLY |
|---|---|---|
| 1-Year Volatility | 14.40% | 38.09% |
| Beta | 0.62 | 0.51 |
| 3-Month Avg. Volume | 4.85M | 3.19M |
Company Profile
Berkshire Hathaway (BRK.B) is classified in the Financials sector (Financial Services), whereas Eli Lilly (LLY) belongs to Health Care (Pharmaceuticals, Biotechnology & Life Sciences) — their GICS classifications point to very different parts of the market.
| Profile Item | BRK.B | LLY |
|---|---|---|
| Name | Berkshire Hathaway Inc. Class B | Eli Lilly and Company |
| Country/Region | United States | United States |
| GICS Sector | Financials | Health Care |
| GICS Industry Group | Financial Services | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Financial Services | Pharmaceuticals |
| GICS Sub-Industry | Multi-Sector Holdings | Pharmaceuticals |
| Market Capitalization | 1,055.24 billion USD | 1,010.34 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | NYSE |
| Listing Date | May 9, 1996 | June 1, 1972 |
| Security Type | Common Stock | Common Stock |
Valuation
Price-to-Earnings Ratio (TTM)
Both Berkshire Hathaway (BRK.B) at 14.56 and Eli Lilly (LLY) at 40.32 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.
BRK.B
Financial Services industry group
14.56
- Max
- 47.33
- Q3
- 25.83
- Median
- 14.56
- BRK.B
- 14.56
- Q1
- 9.03
- Min
- 0.60
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
40.32
- Max
- 77.14
- Q3
- 43.78
- LLY
- 40.32
- Median
- 24.68
- Q1
- 15.27
- Min
- 1.70
Price-to-Sales Ratio (TTM)
On P/S ratio, both Berkshire Hathaway (BRK.B) at 2.81 and Eli Lilly (LLY) at 13.98 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
BRK.B
Financial Services industry group
2.81
- Max
- 9.45
- Q3
- 4.84
- Median
- 2.86
- BRK.B
- 2.81
- Q1
- 1.48
- Min
- -1.12
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
13.98
- Max
- 55.38
- Q3
- 24.42
- LLY
- 13.98
- Median
- 6.98
- Q1
- 3.30
- Min
- 0.01
Price-to-Book Ratio (MRQ)
Berkshire Hathaway (BRK.B) at 0.00 sits in the lower P/B ratio quartile relative to book while Eli Lilly (LLY) at 32.45 prices above its industry range — a wide valuation gap against assets.
BRK.B
Financial Services industry group
0.00
- Max
- 7.24
- Q3
- 3.50
- Median
- 1.63
- Q1
- 0.92
- BRK.B
- 0.00
- Min
- 0.00
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
32.45
- LLY
- 32.45
- Max
- 13.23
- Q3
- 6.38
- Median
- 3.46
- Q1
- 1.64
- Min
- -5.17
Valuation at a Glance
| Metric | BRK.B | LLY |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 14.56 | 40.32 |
| Price-to-Sales Ratio (TTM) | 2.81 | 13.98 |
| Price-to-Book Ratio (MRQ) | 0.00 | 32.45 |
| Free Cash Flow Yield | -- | 0.91% |
Profitability
Return on Equity (TTM)
Eli Lilly (LLY) at 107.46% clears its industry range for ROE, a sharper capital-efficiency signal than Berkshire Hathaway (BRK.B) at 10.50%, which is closer to a typical peer reading.
BRK.B
Financial Services industry group
10.50%
- Max
- 42.17%
- Q3
- 21.40%
- Median
- 12.18%
- BRK.B
- 10.50%
- Q1
- 5.01%
- Min
- -18.74%
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
107.46%
- LLY
- 107.46%
- Max
- 101.32%
- Q3
- 2.92%
- Median
- -31.26%
- Q1
- -62.68%
- Min
- -158.89%
Net Profit Margin (TTM)
Eli Lilly (LLY) at 34.99% converts revenue to bottom-line profit above its industry’s benchmark range, while Berkshire Hathaway (BRK.B) at 19.31% keeps roughly the typical share for its industry.
BRK.B
Financial Services industry group
19.31%
- Max
- 66.55%
- Q3
- 30.41%
- BRK.B
- 19.31%
- Median
- 16.58%
- Q1
- 4.49%
- Min
- -26.88%
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
34.99%
- LLY
- 34.99%
- Max
- 12.76%
- Q3
- 4.00%
- Median
- 0.00%
- Q1
- -2.26%
- Min
- -11.53%
Operating Profit Margin (TTM)
Eli Lilly (LLY) at 49.39% operates in the top operating margin quartile, ahead of Berkshire Hathaway (BRK.B) at 14.35%, which runs around its industry’s norm.
BRK.B
Financial Services industry group
14.35%
- Max
- 95.95%
- Q3
- 50.01%
- Median
- 27.45%
- BRK.B
- 14.35%
- Q1
- 12.28%
- Min
- -36.26%
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
49.39%
- Max
- 100.30%
- LLY
- 49.39%
- Q3
- 4.40%
- Median
- 0.00%
- Q1
- -131.52%
- Min
- -333.43%
Profitability at a Glance
| Metric | BRK.B | LLY |
|---|---|---|
| Return on Equity (TTM) | 10.50% | 107.46% |
| Return on Assets (TTM) | 5.39% | 20.74% |
| Net Profit Margin (TTM) | 19.31% | 34.99% |
| Operating Profit Margin (TTM) | 14.35% | 49.39% |
| Gross Profit Margin (TTM) | -- | 82.83% |
Growth
Revenue Growth
Revenue Growth at a Glance
| Metric | BRK.B | LLY |
|---|---|---|
| 1-Year Revenue Growth | -3.23% | 44.70% |
| 3-Year Revenue CAGR | 20.59% | 31.69% |
EPS Growth
EPS Growth at a Glance
| Metric | BRK.B | LLY |
|---|---|---|
| 1-Year EPS Growth | -24.78% | 95.99% |
| 3-Year EPS CAGR | -- | 51.71% |
Financial Strength
Current Ratio (MRQ)
Eli Lilly (LLY) shows current ratio of 1.50; Berkshire Hathaway (BRK.B) doesn’t get one — Financial Services balance sheets aren’t split into current and non-current buckets, so short-term liquidity there is judged through regulatory measures instead.
BRK.B
Financial Services industry group
--
- BRK.B
- --
- Max
- --
- Q3
- --
- Median
- --
- Q1
- --
- Min
- --
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.50
- Max
- 24.81
- Q3
- 11.75
- Median
- 5.57
- Q1
- 2.69
- LLY
- 1.50
- Min
- 0.23
Debt-to-Equity Ratio (MRQ)
Eli Lilly (LLY) shows debt-to-equity ratio of 1.39; for Berkshire Hathaway (BRK.B) the ratio is set aside — in Financial Services, balance-sheet leverage is part of the business model itself, so capital-adequacy measures do the job this ratio does elsewhere.
BRK.B
Financial Services industry group
--
- BRK.B
- --
- Max
- --
- Q3
- --
- Median
- --
- Q1
- --
- Min
- --
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.39
- Max
- 1.60
- LLY
- 1.39
- Q3
- 0.68
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength at a Glance
| Metric | BRK.B | LLY |
|---|---|---|
| Current Ratio (MRQ) | -- | 1.50 |
| Debt-to-Equity Ratio (MRQ) | -- | 1.39 |
| Net Debt / EBITDA | -- | 1.05 |
Dividends
Dividend Yield (TTM)
Berkshire Hathaway (BRK.B) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Eli Lilly (LLY) reports a yield of 0.61%, ranking against industry peers normally.
BRK.B
Financial Services industry group
0.00%
- Max
- 18.40%
- Q3
- 7.73%
- Median
- 1.93%
- BRK.B
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.61%
- LLY
- 0.61%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Berkshire Hathaway (BRK.B) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Eli Lilly (LLY) reports a payout of 22.13%, ranking against industry peers normally.
BRK.B
Financial Services industry group
0.00%
- Max
- 228.57%
- Q3
- 95.72%
- Median
- 25.56%
- BRK.B
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
22.13%
- LLY
- 22.13%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividends at a Glance
| Metric | BRK.B | LLY |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.61% |
| Dividend Payout Ratio (TTM) | 0.00% | 22.13% |